Editor:
CureVac AG
Friedrich-Miescher-Str. 15
72076 Tübingen
Deutschland

T +49 7071 9883 – 0
F +49 7071 9883 – 1101
E info@curevac.com

Represented by and responsible for the contents:
(Responsible for content according to § 55 Abs. 2 RStV)

Executive Board:
Franz-Werner Haas, Ph.D., LL.M.; Mariola Fotin-Mleczek, Ph.D.; Florian von der Mülbe, Ph.D., MBA;
Pierre Kemula, B.Sc.; Igor Splawski, Ph.D.; Bernd Winterhalter, MD, Ph.D.

Chairman of the Supervisory Board:
Jean Stéphenne

Register Court:
Stuttgart

Commercial register:
HRB 754041

VAT identification number:
DE 221 393 632

Competent Authority:
Regierungspräsidium Tübingen

Disclaimer:

Note regarding forward-looking statements

This website of CureVac (the “company”) contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express opinions, expectations, beliefs, plans, objectives, assumptions or projections of the “company” regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur.

The information contained on this website was current as of the date presented. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.


Website Concept & Design:
klargedacht, Berlin